Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1a/b, Open-Label, Dose-Escalation and Expansion Study of IK-175, an Oral Aryl Hydrocarbon Receptor (AHR) Inhibitor, as a Single Agent and in Combination With Nivolumab, a PD-1 Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04200963
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:54.449573+00:00
Published At
2024-03-15T00:00:00+00:00
Record Updated At
2024-03-15
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Urothelial Carcinoma", "Urothelial Carcinoma Bladder", "Bladder Cancer", "Bladder Disease", "Solid Tumor", "Solid Carcinoma", "Solid Tumor, Adult", "Metastatic Cancer", "Advanced Solid Tumor", "Advanced Cancer", "Metastatic Bladder Cancer", "Metastatic Urothelial Carcinoma", "Locally Advanced Solid Tumor", "Neoplasms", "Neoplasm Metastasis", "Neoplasm Malignant", "Neoplasm, Bladder", "Urothelial Neoplasm", "Neoplasm, Urinary Bladder", "Bladder Neoplasm", "Bladder Urothelial Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-03-15"
protocolSection.identificationModule.nctId
"NCT04200963"
protocolSection.identificationModule.officialTitle
"A Phase 1a/b, Open-Label, Dose-Escalation and Expansion Study of IK-175, an Oral Aryl Hydrocarbon Receptor (AHR) Inhibitor, as a Single Agent and in Combination With Nivolumab, a PD-1 Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Urothelial Carcinoma Bladder (protocolSection.conditionsModule.conditions)
  • Bladder Cancer (protocolSection.conditionsModule.conditions)
  • Bladder Disease (protocolSection.conditionsModule.conditions)
  • Solid Tumor (protocolSection.conditionsModule.conditions)
  • Solid Carcinoma (protocolSection.conditionsModule.conditions)
  • Solid Tumor, Adult (protocolSection.conditionsModule.conditions)
  • Metastatic Cancer (protocolSection.conditionsModule.conditions)
  • Advanced Solid Tumor (protocolSection.conditionsModule.conditions)
  • Advanced Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Bladder Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Advanced Solid Tumor (protocolSection.conditionsModule.conditions)
  • Neoplasms (protocolSection.conditionsModule.conditions)
  • Neoplasm Metastasis (protocolSection.conditionsModule.conditions)
  • Neoplasm Malignant (protocolSection.conditionsModule.conditions)
  • Neoplasm, Bladder (protocolSection.conditionsModule.conditions)
  • Urothelial Neoplasm (protocolSection.conditionsModule.conditions)
  • Neoplasm, Urinary Bladder (protocolSection.conditionsModule.conditions)
  • Bladder Neoplasm (protocolSection.conditionsModule.conditions)
  • Bladder Urothelial Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.